SDZ 220-581

• Description:

  SDZ 220-581 is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  IGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/SDZ-220-581.html

• Purity:

  98.76

• Solubility:

  DMSO : 8.57 mg/mL (ultrasonic; warming)

• Smiles:

  ClC1=CC=CC=C1C2=CC(C[C@H](N)C(O)=O)=CC(CP(O)(O)=O)=C2

• Molecular Formula:

  C16H17ClNO5P

• Molecular Weight:

  369.74

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Urwyler S, Campbell E, Fricker G, Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Neuropharmacology. 1996 Jun;35 (6) :655-69.|[2]Gilmour G, et al. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  NMDA Receptor

• CAS Number:

  [174575-17-8]